Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
05:34pm, Tuesday, 14'th Jan 2025
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge fu
5 ‘Strong Buy' High-Yield Dividend Stocks Are Top Wall Street Picks for 2025
03:15pm, Tuesday, 14'th Jan 2025
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and offer a promising avenue for total return.
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
02:10pm, Tuesday, 14'th Jan 2025
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. PFE Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.”
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
11:54am, Tuesday, 14'th Jan 2025
Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline
04:20pm, Monday, 13'th Jan 2025
Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more.
Pfizer Inc. (PFE) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
03:26pm, Monday, 13'th Jan 2025
Pfizer Inc. (NYSE:PFE ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 12:45 PM ET Company Participants Albert Bourla - Chairman & Chief Executive Officer Conference Call Particip
Pfizer going 'all in' on obesity drug development, CEO Bourla says
01:35pm, Monday, 13'th Jan 2025
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Exeuctive Officer Albert Bourla said at the JPMorgan Healthcar
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
11:16am, Monday, 13'th Jan 2025
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
3 High-Yield Dividend Stocks to Buy in 2025
09:00am, Monday, 13'th Jan 2025
High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great additions to your portfolio.
Investing $5,000 Just Once in These 3 Ultra-High-Yielding Stocks Could Earn You $320 in Passive Income Every Year
05:10am, Monday, 13'th Jan 2025
Dividend stocks can be a great way to play the market. They typically provide reliable passive income and can offer a less volatile strategy than solely investing for appreciation.
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
11:45pm, Sunday, 12'th Jan 2025
The 'Dogs of the Dow' strategy can be applied to Pfizer in 2025 for its 6.4% dividend and a former 'Dog.'. PFE's growth recovery, historical cheap valuation, and positive investment sentiment make it
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
02:54pm, Friday, 10'th Jan 2025
On Thursday, Truist initiated coverage on BioNTech SE BNTX, a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc PFE.
Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
07:45am, Friday, 10'th Jan 2025
For most investors, generating consistent income alongside capital appreciation is a common goal. For those seeking a blend of stability and yield, high-yield blue-chip stocks often present a compelli
Pfizer's bladder cancer therapy meets main goal in late-stage study
06:51am, Friday, 10'th Jan 2025
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on Fr
